Istituto Ortopedico Rizzoli — Clinical Trial Site

23 Registered trials

13 Currently recruiting

Organisation

Istituto Ortopedico Rizzoli

Location

Bologna, Italy

Identifier

ORG-100009694

Address

Via Giulio Cesare Pupilli 1, 40136, Italy

Departments

2802:SSD Medicina e Reumatologia
4047: S.S.D. Medicina e Reumatologia
Chemotherapy Unit
Department of Rare Skeletal Disorders
Dipartimento di malattie rare scheletriche
Dipartimento Patologie Ortopediche-Traumatologiche Specialistiche
Medical Oncology
Oncologia
Osteoncologia, Sarcomi dell'Osso e dei Tessuti Molli e Terapie Innovative
Osteoncologia, Sarcomi dell'osso e dei tessuti molli, e Terapie Innovative
Osteoncology, Bone and Soft Tissue Sarcoma and Innovative Therapies
Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies Unit
Research, Innovation and Technology Department
Reumatology
SC Osteoncologia sarcomi dell'osso e dei tessuti molli e terapie innovative
SC Osteoncologia, Sarcomi dell'Osso e dei tessuti Molli e Terapia Innovativa
SC Osteoncology Unit
SSD chemioterapia dei tumori dell'apparato musscolo scheletrico
SSD Chemioterapia Rizzoli

Clinical trials at this site (23)

Search interface

A multi-centre, single-arm study to demonstrate the efficacy of bone marrow allogeneic mesenchymal cells combined with biomaterial (combined… Recruiting

2025-520841-60-00 Delayed consolidation or non-union long bone fracture 5 2026-04-24
A study to investigate efficacy and safety of INT230-6 compared with US standard of care in participants aged ≥ 18 years old with metastatic… Recruiting

2024-512423-36-00 Undifferentiated pleomorphic sarcoma 5 2024-11-20
A Phase III, Multicentre, Randomised, Double-Blind Study to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Subjects with Teno… Recruiting

2023-510422-32-00 Tenosynovial Giant Cell Tumour 5 2024-09-10
Metformin as maintenance therapy in bone sarcomas at high risk of relapse Recruiting

2024-515639-32-00 bone sarcoma 4 2024-07-30
A clinical study of ABSK021 in Patients with Tenosynovial Giant Cell Tumor to determine whether the study drug is safe and how well the ant… Recruiting

2023-503245-58-00 Tenosynovial Giant Cell Tumor 5 2023-10-04
A Phase 3 program evaluating the effect of filgotinib in subjects with active axial spondyloarthritis Recruiting

2022-501354-10-01 axial spondyloarthritis 5 2023-06-21
Phase II, multicentre, randomised, open-label trial with MAP +/- denosumab regimen for the treatment of patients with metastatic osteosarcom… Recruiting

2024-518167-35-01 Patients with Metastatic Osteosarcoma 4 2025-12-19
An Open-label, Phase 4 Study of Nirogacestat in Adult Premenopausal Females with Desmoid Tumor/Aggressive Fibromatosis (DT/AF). Recruiting

2024-515215-21-00 DESMOID TUMOURS/AGGRESSIVE FIBROMATOSIS (DT/AF) 6 2025-10-24
Matrix-Directed Therapy In Older Adolescents And Adults With Osteogenesis Imperfecta Recruiting

2024-515516-50-00 Osteogenesis Imperfecta 4 2025-09-18
Ivosidenib in participants with locally advanced or metastatic conventional chondrosarcoma untreated or previously treated with 1 or 2 syste… Recruiting

2023-508507-20-00 Locally advanced or metastatic conventional chondrosarc 5 2025-04-03
A Randomized & Observational phase II trial comparing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally adva… Recruiting

2024-513820-40-00 Metastatic or locally advanced leiomyosarcoma 4 2021-10-29
Phase II study on trabectedin in adults and young adults HEY1-NOCA2 positive skeletal and extra-skeletal mesenchymal chondrosarcoma (MCS) Recruiting

2024-514319-85-00 Advanced rearranged mesenchymal chondrosarcoma 4 2021-09-14
rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma Recruiting

2024-516078-31-00 Recurrent and Primary Refractory Ewing Sarcoma 10 2015-05-05
Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M… Ended

2022-502975-45-00 Metastatic leiomyosarcoma 5 2023-12-12
A study to test product setrusumab in subjects with brittle bone syndrome. Ended

2024-510919-29-00 Osteogenesis imperfecta (OI) 10 2023-05-08
A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenanc… Ended

2023-509320-17-00 non-radiographic axial spondyloarthritis 6 2023-03-28
A Phase 2 study of INBRX-109 in adults with a type of unresectable or metastasized cancer of the bones and joints (Conventional Chondrosarco… Ended

2024-517528-20-00 Unresectable or metastatic conventional chondrosarcoma 4 2022-04-19
Efficacy and Safety of L19TNF in Previously Treated Patients With Advanced Stage or Metastatic Soft-tissue Sarcoma Ended

2024-512704-20-00 Unresectable and/or metastatic soft-tissue sarcoma afte 4 2020-06-22
A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients wit… Ended

2024-514933-39-00 Patients with Advanced Tumors and Tenosynovial Giant Ce 7 2020-05-26
L19TNF plus doxorubicin in patients with STS Ended

2024-512789-32-00 Unresectable or metastatic soft tissue sarcoma 5 2017-10-09
Phase I-II trial of sunitinib and/or nivolumab plus chemotherapy in advanced soft tissue and bone sarcomas Ended

2024-514776-40-00 Advanced soft tissue and bone sarcomas 9 2017-03-23
Study of efficacy and safety of secukinumab in participants with moderate-severe rotator cuff tendinopathy Ended

2022-502080-38-00 Moderate to severe rotator cuff tendinopathy 5 2023-10-16
A Phase 2 Study Evaluating Abemaciclib in Combination with Irinotecan and Temozolomide in Participants with Ewing's Sarcoma Ended

2023-506772-28-00 Ewings Sarcoma 4 2022-10-07